There are currently 2860 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SNV1521 in Participants with Advanced Solid Tumors
NCT06220864
Recruiting
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
NCT02249923
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Texas Children's, Houston, Texas
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Register for Updates
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
NCT03742245
Recruiting
The purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Houston Methodist Cancer Center, Houston, Texas
Conditions: Breast Cancer Metastatic, Breast Cancer
Register for Updates
ERP to Improve Functioning in Veterans With OCD
NCT05240924
Recruiting
Obsessive compulsive disorder (OCD) is a debilitating psychiatric illness impacting work, social, and family functioning. Exposure and Response Prevention (ERP) is the sole evidence-based psychotherapy for OCD; however, no randomized controlled trials (RCTs) have examined the effectiveness of ERP among Veterans or individuals with both OCD and posttraumatic stress disorder (PTSD). This 4-year Hybrid Type I trial will compare outcomes of ERP to those of a control condition among Veterans with OCD... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Obsessive Compulsive Disorder (OCD), Comorbid Post-Traumatic Stress Disorder and OCD
Register for Updates
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT05822583
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Houston Methodist Research Institute (Site 301-028), Houston, Texas +1 locations
Conditions: COVID-19
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Ventavia Research Group, Houston, Texas +2 locations
Conditions: SARS-CoV-2
Register for Updates
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211
Recruiting
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/07/2025
Locations: Research Site, Houston, Texas
Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372
Recruiting
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/07/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mesothelioma
Register for Updates
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
NCT03382977
Recruiting
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma Multiforme
Register for Updates
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717
Recruiting
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Register for Updates
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
NCT06377930
Recruiting
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Focal Onset Seizures
Register for Updates